Acta Diabetologica

, Volume 33, Issue 1, pp 48–52 | Cite as

Analysis of direct cost of standard compared with intensive insulin treatment of insulin-dependent diabetes mellitus and cost of complications

  • Z. Stern
  • R. Levy
Original

Abstract

Insulin-dependent diabetes mellitus (type 1) is accompanied by long-term complications: retinopathy, nephropathy, neuropathy, as well as macrovascular complications. We compared the direct cost of standard insulin treatment in type 1 patients with that of intensified treatment as well as the direct cost of their complications during the two treatment modes for 35 years' duration of disease. According to our model calculations, the direct cost of basic intensified insulin treatment is $3300 per year, about three times more than that of the standard insulin treatment. However, for the period of 35 years, the cost of complications associated with intensified insulin treatment is lower, while the total cost of intensified treatment, over 35 years, is higher than that of the standard treatment. Thus, looking from the health provider point of view and relating only to economic analysis, intensified insulin treatment encompassing all type 1 patients is not cost-beneficial. Therefore, the decision to adopt this type of therapy should be based on the combination of medical, ethical, political, and economical principles, and applied to selected, well motivated, and prepared patient groups, in whom compliance to intensified treatment would be expected to prevent or delay the onset of complications. According to cost analysis, nephropathy is the most common and severest complication, and intensive treatment promises to be most effective in this group of patients.

Key words

Analysis of direct cost Insulin-dependent diabetes mellitus Standard and intensified insulin treatment 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Feldi-Rasmussen B, Mathiesen ER, Jensen T, Lauritzen T, Deckert T, Effect of improved metabolic control on loss of kidney function in type 1 (insulin-dependent) diabetic patients: an update of the Steno studies. Diabetologia 34:164–170, 1991Google Scholar
  2. 2.
    Dahl-Jorgensen K, Brinchmann-Hansen O, Hanssen KF, Ganes T, Kierule P, Smeland E, Sandvik L, Aagenaes O, Effect of near normoglycemia for two years on progression of early diabetic retinopathy, nephropathy and neuropathy: the Oslo study. BMJ 293:1195–1199, 1986Google Scholar
  3. 3.
    Reichard P, Nilsson B-Y, Rosenqvist U, The effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus. N Engl J Med 329:304–309, 1993Google Scholar
  4. 4.
    The Diabetes Control and Complications Trial Research Group, The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin dependent diabetes mellitus. N Engl J Med 329:977–986, 1993Google Scholar
  5. 5.
    Raskin P, The DCCT-finally!!. J Diabetes Complications 7:214–215, 1993Google Scholar
  6. 6.
    Herman W, DasBach E, Songer T, Thompson E, Crofford O, Assessing the impact of intensive insulin therapy on health care system. Diabetes Rev 2:384–388, 1994Google Scholar
  7. 7.
    Stern Z, Levy R, The direct cost of type 1 diabetes mellitus in israel. Diabetic Med 11:528–534, 1994Google Scholar
  8. 8.
    American Diabetes Association, Diabetes 1993 Vital Statistics. ADA, 1993Google Scholar
  9. 9.
    Diabetes Control and Complications Trial Research Group, Implementation of treatment protocols in Diabetes Control and Complications Trial. Diabetes Care 18:361–376, 1995Google Scholar
  10. 10.
    Andersen AR, Sandahl Christiannsen J, Andersen JK, Kreiner S, Deckert T, Diabetic nephropathy in type 1 (insulin dependent) diabetes: an epidemiologic study. Diabetologia 25:494–501, 1993Google Scholar
  11. 11.
    Knuiman MW, Welborn TA, McCann VJ, Stanton KG, Constable IJ, Prevalence of diabetic complications in relation to risk factors. Diabetes 36:1332–1339, 1986Google Scholar
  12. 12.
    Fries JF, Crapo LM, Vitality and aging. W. H. Freeman, San Francisco, 1981Google Scholar
  13. 13.
    Lasker RD, The Diabetes Control and Complications trial — implications for policy and practice. N Engl J Med 329:1035–1036, 1993Google Scholar
  14. 14.
    Dunn SM, Hoskins PL, Constantino M, Overland J, Yue DK, Turtle J, Diabetic management. Diabetes Rev 2:389–402, 1994Google Scholar
  15. 15.
    World Health Organization, Diabetes mellitus. Report of a WHO study group. (Technical Report Series 727) WHO, Geneva, 1985Google Scholar
  16. 16.
    Rubin RJ, Altman WM, Mendelson DN, Health care expenditures for people with diabetes mellitus. J Clin Endocrinol Metab 78:809A-F, 1994Google Scholar

Copyright information

© Springer-Verlag 1996

Authors and Affiliations

  • Z. Stern
    • 1
  • R. Levy
    • 1
  1. 1.Hadassah Hebrew-University HospitalJerusalemIsrael

Personalised recommendations